Preoperative and Postoperative Sublingual Misoprostol for Prevention of Postpartum Blood Loss in Cesarean Section

Phase 4

Completed

• Conditions: Postpartum Hemorrhage
• Interventions: Drug: Misoprostol

• Registration Number: NCT03591913
• Lead Sponsor: Assiut University

Brief Summary

Cesarean section is one of the most common major surgical operations among women. In 2015, the incidence of cesarean section in Woman Health Hospital in Assiut University accounts for 51.3 % of all deliveries

Detailed Description

Not available

Study Timeline

• Study Start: 2018-02-01
• Study First Submitted: 2018-07-08
• Study First Submitted QC: 2018-07-08
• Study First Posted: 2018-07-19
• Primary Completion: 2018-08-01
• Status Verified: 2018-09
• Study Completion: 2018-09-01
• Last Update Submitted: 2018-09-17
• Last Update Posted: 2018-09-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 500

Inclusion Criteria

• All pregnant women who will undergo elective lower segment cesarean section
• term ( ≥ 37 weeks)
• normal fetal heart tracing.

Exclusion Criteria

• Placenta previa-Rupture uterus
• Classical cesarean section
• Preterm delivery
• Hypertensive disorders of pregnancy
• Bleeding tendency
• Previous history of postpartum hemorrhage
• Concurrent anticoagulant therapy
• Concurrent long-term use of steroids
• Fetal distress
• Antepartum haemorrhage

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
control group	Misoprostol	will receive sublingual misoprostol immediately after skin closure
study group	Misoprostol	will receive sublingual misoprostol immediately after urinary catheterization and before skin incision

Primary Outcome Measures

Name	Time	Method
mean intraoperative blood loss	24 hours	Blood loss estimation will commence immediately following the skin incision

Trial Locations

Locations (1)

Ahmed Abbas; 🇪🇬 Assiut, Cairo, Egypt